LEADER 03866nam  22006855  450 
001 9910298325403321
005 20230719191714.0
010   $a3-662-43836-4
024 7 $a10.1007/978-3-662-43836-7
035   $a(CKB)3710000000228354
035   $a(EBL)1966823
035   $a(OCoLC)908086253
035   $a(SSID)ssj0001353625
035   $a(PQKBManifestationID)11813554
035   $a(PQKBTitleCode)TC0001353625
035   $a(PQKBWorkID)11315595
035   $a(PQKB)11636234
035   $a(MiAaPQ)EBC1966823
035   $a(DE-He213)978-3-662-43836-7
035   $a(PPN)181353237
035   $a(EXLCZ)993710000000228354
100   $a20140901d2014      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aCommercial Plant-Produced Recombinant Protein Products $eCase Studies /$fedited by John A. Howard, Elizabeth E. Hood
205   $a1st ed. 2014.
210  1$aBerlin, Heidelberg :$cSpringer Berlin Heidelberg :$cImprint: Springer,$d2014.
215   $a1 online resource (282 p.)
225 1 $aBiotechnology in Agriculture and Forestry,$x2512-3696 ;$v68
300   $aDescription based upon print version of record.
311   $a3-662-43835-6 
320   $aIncludes bibliographical references at the end of each chapters and index.
327   $aIntroduction ? Plant-produced protein products -- Commercial Plant-Produced Recombinant Avidin -- Molecular farming in plants ? the long road to the market -- TrypZean?: an animal-free alternative to bovine trypsin -- Production of Pharmaceutical Grade Recombinant Native Aprotinin and Non-Oxidized Aprotinin-Variants Under Greenhouse and Field Conditions -- Influenza virus-like particles produced in Nicotiana benthamiana protect against a lethal viral challenge in mice -- Plant-Produced Recombinant Transmission Blocking Vaccine Candidates to Combat Malaria -- An oral vaccine for TGEV immunization of pigs -- Edible Rabies Vaccines -- Newcastle disease vaccines -- An oral vaccine for hepatitis B: challenges, setbacks and breakthroughs -- Commercial Plant-Produced Recombinant Cellulases for Biomass Conversion -- Brazzein: A High Intensity Natural Sweetener -- The Future of Plant-Produced Pharmaceuticals and Industrial Proteins.
330   $aAttention has recently turned to using plants as hosts for the production of commercially important proteins. The twelve case studies in this volume present successful strategies for using plants to produce industrial and pharmaceutical proteins and vaccine antigens. They examine in detail projects that have commercial potential or products that have already been commercialized, illustrating the advantages that plants offer over bacterial, fungal or animal cell-culture hosts. There are many indications that plant protein production marks the beginning of a new paradigm for the commercial production of proteins that, over the next decade, will expand dramatically.
410  0$aBiotechnology in Agriculture and Forestry,$x2512-3696 ;$v68
606   $aPlant biotechnology
606   $aBiotechnology
606   $aPharmaceutical chemistry
606   $aPlant Biotechnology
606   $aBiotechnology
606   $aPharmaceutics
615  0$aPlant biotechnology.
615  0$aBiotechnology.
615  0$aPharmaceutical chemistry.
615 14$aPlant Biotechnology.
615 24$aBiotechnology.
615 24$aPharmaceutics.
676   $a660.6
702   $aHoward$b John A$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aHood$b Elizabeth E$4edt$4http://id.loc.gov/vocabulary/relators/edt
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910298325403321
996   $aCommercial Plant-Produced Recombinant Protein Products$92536198
997   $aUNINA